Skip to main content
. Author manuscript; available in PMC: 2021 Jun 2.
Published in final edited form as: Radiographics. 2021 Feb 5;41(2):321–337. doi: 10.1148/rg.2021200101

Figure 4.

Figure 4.

Images from the GE SenoClaire DBT system, which was approved by the FDA in 2014. Mediolateral oblique diagnostic-quality two-dimensional (a), synthetic V-preview (b), and DBT (c) images of the right breast in a 78-year-old woman at diagnostic imaging show an irregular mass in the inferior breast (arrow), which is consistent with a biopsy proven ER+/PR+/HER2− invasive lobular carcinoma.